Glaukos Corp (GKOS) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
Total Assets Chart for Glaukos Corp
Glaukos Corp (GKOS) total assets for FY2025 were USD 893.5M, a -8.3% change from FY2024. Glaukos Corp's total assets grew from USD 5.2M in 2012 to USD 893.5M in 2025 (17198.9% over 13 years). Total assets compound annual growth rate: 5-year CAGR of -2.3%, 10-year CAGR of 22.6%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $10.55B
- Implied Share Price
- $178.88
- Enterprise Value
- $9.34B
- Revenue (TTM)
- $612.84M
- EBITDA
- -$37.02M
- Profit Margin
- -30.69%
- Trailing P/E
- —
- Forward P/E
- 1666.67
- Price/Book (MRQ)
- 6.33
- Price/Sales (TTM)
- 17.22
- EV/EBITDA
- -57.89
- EV/Revenue
- 10.80
- Dividend Yield
- —
- Book Value
- $11.60
- Free Cash Flow (FY2025)
- -$54.01M
- Free Cash Flow Yield
- -0.51%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.